



## Alset International Limited

(Incorporated in the Republic of Singapore)  
(Company Registration Number 200916763W)

---

**PRESS RELEASE ISSUED BY DOCUMENT SECURITY SYSTEMS, INC.**

**IMPACT BIOMEDICAL, INC. COMMENCES EFFICACY TESTING OF PAN-CORONAVIRUS VACCINE**

---

The Board of Directors (the “**Board**”) of Alset International Limited (Stock Code: 40V) (the “**Company**”) wishes to announce that its related company, Document Security Systems, Inc. (“**DSS**”), has issued a press release titled “*Impact BioMedical to Begin Efficacy Testing of Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary - Innate Immune, Inc.*” (the “**Press Release**”) on 1 October 2020 (Eastern Time).

A copy of the Press Release issued by DSS is attached to this announcement.

The Press Release states, *inter alia*, that Impact BioMedical, Inc. has commenced efficacy testing of a pan-coronavirus vaccine (i.e. a special type of vaccine designed to protect against multiple coronaviruses) through its newly formed wholly-owned subsidiary, Innate Immune, Inc..

Shareholders are advised to refer to the full text of the Press Release, attached to this announcement, for further details.

The efficacy testing of the pan-coronavirus vaccine is not expected to have a material impact on the net tangible assets per share and the earnings per share of the Company for the current financial year ending 31 December 2020.

### **Cautionary Statement**

**Shareholders and potential investors of the Company should note that there is no certainty or assurance as at the date of this announcement that the pan-coronavirus vaccine will be effective as a vaccine against any coronavirus or that the pan-coronavirus vaccine will be commercialised.**

**Shareholders and potential investors of the Company are advised to read this announcement and any further announcements made by the Company carefully. Shareholders and potential investors of the Company are advised to refrain from taking any action with respect to their securities in the Company which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. Shareholders and potential investors of the Company should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.**

By Order of the Board  
**Alset International Limited**

Chan Heng Fai  
Executive Chairman, Executive Director and Chief Executive Officer

2 October 2020

---

*This announcement has been reviewed by the Company's Sponsor, Hong Leong Finance Limited. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Vera Leong, Vice President, Hong Leong Finance Limited, at 16 Raffles Quay, #01-05 Hong Leong Building, Singapore 048581, telephone (+65) 6415 9881.*